Latoprost RT BKC Free Eye Drop contains Latanoprost 0.005% w/v, a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost acts by increasing the outflow of aqueous humor via the uveoscleral pathway, thereby effectively lowering IOP and reducing the risk of optic nerve damage and visual field loss associated with glaucoma. The formulation is benzalkonium chloride (BKC) free, minimizing the risk of preservative-related ocular surface irritation and making it suitable for patients with sensitive eyes or those requiring long-term therapy. Latoprost RT is administered as one drop in the affected eye(s) once daily in the evening, providing convenient dosing and sustained IOP control over 24 hours. Clinical studies have demonstrated its efficacy in significantly reducing IOP compared to baseline and other antiglaucoma agents, with a favorable safety profile. Common adverse effects may include mild ocular hyperemia, eyelash growth, and iris pigmentation changes, which are generally well tolerated. Latoprost RT BKC Free Eye Drop should be used under ophthalmologic supervision, with regular monitoring of intraocular pressure and ocular health to optimize therapeutic outcomes and minimize potential side effects.